CeriBell, Inc. (CBLL) FinancialsCBLLCeriBell, Inc.

CeriBell, Inc. (CBLL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is EEG recorders and EEG headbands, point in time, accounting for 75.6% of total sales, equivalent to $21.24M. Another important revenue stream is EEG portal and Clarity subscriptions, over time. Understanding this composition is critical for investors evaluating how CBLL navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, CeriBell, Inc. maintains a gross margin of 92.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -71.11%, while the net margin is -68.58%. These profitability ratios, combined with a Return on Equity (ROE) of -43.93%, provide a clear picture of how effectively CBLL converts its operational activities into shareholder value.

In the context of the broader market, CBLL competes directly with industry leaders such as CSTL and PRCT. With a market capitalization of $1.06B, it holds a significant position in the sector. When comparing efficiency, CBLL's gross margin of 92.32% stands against CSTL's 74.94% and PRCT's 66.01%. Such benchmarking helps identify whether CeriBell, Inc. is trading at a premium or discount relative to its financial performance.

CeriBell has shown significant revenue growth, with Q2 2026 revenue at $28.1 million, a 33% increase year-over-year. The gross margin has improved to 92%, reflecting effective cost management despite rising operating expenses.